Literature DB >> 25440775

Platelet factor 4 limits Th17 differentiation and ischaemia-reperfusion injury after liver transplantation in mice.

H Guo1, Y Wang, Z Zhao, X Shao.   

Abstract

Liver ischaemia/reperfusion injury (IRI) is a serious pathologic process encountered in a number of clinical syndromes including liver transplantation, liver resection, trauma and haemorrhagic shock. Platelet factor 4 (PF4) was the first discovered CXC chemokine and is found in platelet granules at very high concentration. In this study, we provide strong evidence that PF4 is involved directly in liver innate immune response against IRI by regulating Th17 differentiation. PF4 deficiency aggravates liver IRI, as shown by higher serum alanine aminotransferase (ALT) levels and Suzuki scores. PF4 deficiency promotes Th17 response with higher levels of IL-23, IL-6 and IL-17, which aggravates liver IRI. Furthermore, PF4 deficiency limits suppressor of cytokine signalling 3 (SOCS3) expressions, and PF4 fails to suppress expression of IL-17 in cells transfected with SOCS3 SiRNA. In conclusion, PF4 limits liver IRI through IL-17 inhibition via upregulation of SOCS3.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25440775     DOI: 10.1111/sji.12257

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

1.  Thrombospondin-1, Platelet Factor 4, and Galectin-1 Are Associated with Engraftment in Patients with Sickle Cell Disease who Underwent Haploidentical Hematopoietic Stem Cell Transplantation.

Authors:  Ahmad Shaikh; Purevdorj B Olkhanud; Arunakumar Gangaplara; Abdoul Kone; Sajni Patel; Marjan Gucek; Courtney D Fitzhugh
Journal:  Transplant Cell Ther       Date:  2022-02-04

2.  The Blood Proteoform Atlas: A reference map of proteoforms in human hematopoietic cells.

Authors:  Rafael D Melani; Vincent R Gerbasi; Lissa C Anderson; Jacek W Sikora; Timothy K Toby; Josiah E Hutton; David S Butcher; Fernanda Negrão; Henrique S Seckler; Kristina Srzentić; Luca Fornelli; Jeannie M Camarillo; Richard D LeDuc; Anthony J Cesnik; Emma Lundberg; Joseph B Greer; Ryan T Fellers; Matthew T Robey; Caroline J DeHart; Eleonora Forte; Christopher L Hendrickson; Susan E Abbatiello; Paul M Thomas; Andy I Kokaji; Josh Levitsky; Neil L Kelleher
Journal:  Science       Date:  2022-01-27       Impact factor: 63.714

3.  Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas.

Authors:  Ming Zhang; Liying Gao; Xiaofeng Liu; Fang Dong; Qun Su; Yanping Zhang; Fengju Li; Hulan Wang; Pengbing Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-05       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.